BIO vs CPHI · rev $2.58B vs rev $4.1M
BIO (BIO) versus China Pharma Holdings Inc (CPHI) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
China Pharma Holdings Inc (CPHI) is a drug manufacturers - specialty & generic company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
Latest reported CPHI revenue for 2025-12-31 was $4.1M. Net income was -$3.2M. Revenue was down 8.5% from 2024-12-31 to 2025-12-31. CPHI currently screens at market cap $29.0M.
BIO currently screens at market cap $0. CPHI currently screens at market cap $29.0M.
Not investment advice. Open the BIO and CPHI stock pages for the full models.
Not investment advice.